Stereoselective central nervous system effects of the R- and S-isomers of the GABA uptake blocker N-(4,4-di-(3-methylthien-2-yl)but-3-enyl) nipecotic acid in the rat

被引:12
作者
Cleton, A
de Greef, HJMM
Edelbroek, PM
Voskuyl, RA
Danhof, M
机构
[1] Leiden Univ, Div Pharmacol, Leiden Amsterdam Ctr Drug Res, NL-2300 RA Leiden, Netherlands
[2] Stichting Epilepsie Instellingen Nederland, NL-2103 SW Heemstede, Netherlands
[3] Leiden Univ, Ctr Med, Dept Physiol, NL-2300 RC Leiden, Netherlands
关键词
pharmacokinetics; pharmacodynamics; effect compartment; tiagabine; GABA uptake inhibitor; GABA uptake transporter;
D O I
10.1038/sj.bjp.0702962
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The 'effect compartment' model was applied to characterize the pharmacodynamics of the R and S-isomers of tiagabine in conscious rats in vivo using increase in the beta activity of the EEG as a pharmacodynamic endpoint. 2 No pharmacokinetic differences in plasma were observed between R- and S-tiagabine. The values for clearance and volume of distribution at steady-state were 103 +/- 10 versus 90+/-6 mi min(-1) kg(-1) and 1.8 +/- 0.2 versus 1.6 +/- 0.2 1 kg(-1) for the R- and S-isomer, respectively. In contrast, plasma protein binding showed a statistically significant difference with values of the free fraction of 5.7 +/- 0.5 and 11.4+/-0.6%. In addition the rate constant for transport to the effect compartment was also different with values of 0.027 versus 0.067 min(-1). 3 For both isomers the relationship between concentration and EEG effect was non-linear and successfully characterized on basis of the Hill equation. A statistically significant difference in the value of EC50 Of 328 +/- 11 versus 604 +/- 18 ng ml(-1) was observed for R- and S-tiagabine respectively. The values of the other pharmacodynamic parameters were identical. 4 It is concluded that the differences in in vivo pharmacodynamics of R- and S-tiagabine can be explained by stereoselective differences in both the affinity to the GABA-uptake transporter and the degree of non-specific protein binding in plasma and at the effect site.
引用
收藏
页码:1651 / 1658
页数:8
相关论文
共 24 条
[1]   NEW LOOK AT STATISTICAL-MODEL IDENTIFICATION [J].
AKAIKE, H .
IEEE TRANSACTIONS ON AUTOMATIC CONTROL, 1974, AC19 (06) :716-723
[2]   THE SYNTHESIS OF NOVEL GABA UPTAKE INHIBITORS .1. ELUCIDATION OF THE STRUCTURE-ACTIVITY STUDIES LEADING TO THE CHOICE OF (R)-1-[4,4-BIS(3-METHYL-2-THIENYL)-3-BUTENYL]-3-PIPERIDINECARBOXYLIC ACID (TIAGABINE) AS AN ANTICONVULSANT DRUG CANDIDATE [J].
ANDERSEN, KE ;
BRAESTRUP, C ;
GRONWALD, FC ;
JORGENSEN, AS ;
NIELSEN, EB ;
SONNEWALD, U ;
SORENSEN, PO ;
SUZDAK, PD ;
KNUTSEN, LJS .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (12) :1716-1725
[3]   Gaba transporter heterogeneity: Pharmacology and cellular localization [J].
Borden, LA .
NEUROCHEMISTRY INTERNATIONAL, 1996, 29 (04) :335-356
[4]   TIAGABINE, SK-AND-F 89976-A, CI-966, AND NNC-711 ARE SELECTIVE FOR THE CLONED GABA TRANSPORTER GAT-1 [J].
BORDEN, LA ;
DHAR, TGM ;
SMITH, KE ;
WEINSHANK, RL ;
BRANCHEK, TA ;
GLUCHOWSKI, C .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1994, 269 (02) :219-224
[5]   (R)-N-[4,4-BIS(3-METHYL-2-THIENYL)BUT-3-EN-1-YL]NIPECOTIC ACID BINDS WITH HIGH-AFFINITY TO THE BRAIN GAMMA-AMINOBUTYRIC ACID UPTAKE CARRIER [J].
BRAESTRUP, C ;
NIELSEN, EB ;
SONNEWALD, U ;
KNUTSEN, LJS ;
ANDERSEN, KE ;
JANSEN, JA ;
FREDERIKSEN, K ;
ANDERSEN, PH ;
MORTENSEN, A ;
SUZDAK, PD .
JOURNAL OF NEUROCHEMISTRY, 1990, 54 (02) :639-647
[6]  
CLETON A, 1999, IN PRESS J PHARMACOK
[7]   EFFECT OF CHIRALITY ON PHARMACOKINETICS AND PHARMACODYNAMICS [J].
CROM, WR .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1992, 49 (09) :S9-S14
[8]  
DANHOF M, 1989, TOPICS IN PHARMACEUTICAL SCIENCES 1989, P573
[10]  
FJALLAND B, 1978, ACTA PHARMACOL TOX, V42, P73